Vancomycin (VAN) treatment

Phase 3Small molecule

UUniversity Hospital, Montpellier

Vancomycin (VAN) treatment is one of 50 small molecule programs targeting Toxicity. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToxicityActive, not recruiting

Clostridioides Difficile InfectionActive, not recruiting

Open FractureNot yet recruiting

ToxicityPreclinical

Active, not recruiting

Clostridioides Difficile InfectionPreclinical

Active, not recruiting

Open FracturePhase 3

Not yet recruiting

Competition

Competitive Landscape

223 competitors in Toxicity

#DrugCompanyPhaseTrials

Cytotec

Pfizer

Phase 3

1 2

Mucosta

Otsuka

Phase 3

1 3

Sustiva

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 4

Curcumin

Merck & Co.

Phase 3

1 5

Sodium-Selenite

SStanford University

Phase 3

1 6

Vancomycin (VAN) treatment

UUniversity Hospital, Montpellier

Phase 3

1 7

Cysteine Hydrochloride

Novartis

Preclinical

3 8

Dypirone

UUniversity of Sao Paulo General Hospital

Phase 3

1 9

Imfinzi

AstraZeneca

Preclinical

2 10

Cellcept

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

N/ANot yet recruiting

Clostridioides Difficile Infection

NCT07120490

Phase 3Not yet recruiting

Open Fracture

NCT07659886

Clinical

Trials by Indication[1]

Toxicity1 trial

Retrospective Analysis of Nephrotoxicity During Daptomycin Versus Vancomycin Treatments in High Risk Patients

Completed·UUniversity Hospital, Montpellier··NCT03961503·72 enrolled

Clostridioides difficile Infection1 trial

STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection

Not yet recruiting·MMedical University of Warsaw·N/A·NCT07120490·424 enrolled

Open Fracture1 trial

Implementation of Vancomycin Powder Application in the Emergency Department for Open Fractures

Not yet recruiting·AAtlantic Health System·Phase 3·NCT07659886·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Vancomycin (VAN) treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vancomycin (VAN) treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vancomycin (VAN) treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Montpellier company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Montpellier

Vancomycin (VAN) treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Toxicity1 trial

Clostridioides difficile Infection1 trial

Open Fracture1 trial

References

Drug Info

Quick Facts

Related News